Oral antiplatelet therapy in the secondary prevention of atherothrombotic events

American Journal of Cardiovascular Drugs

Volumn 9, Issue 3, 2009, Pages 197-209

  Ling, Geoffrey ^a   Ovbiagele, Bruce ^b  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; PLACEBO; PRASUGREL; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTERY DISEASE; ATHEROSCLEROSIS; BLEEDING; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DEATH; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; ISCHEMIA; LOADING DRUG DOSE; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; THROMBOSIS; THROMBOSIS PREVENTION;

ADMINISTRATION, ORAL; CLINICAL TRIALS AS TOPIC; EMBOLISM, CHOLESTEROL; HUMANS; MODELS, BIOLOGICAL; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; SECONDARY PREVENTION;

EID: 66849101992     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03256575     Document Type: Review

References (62)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics: 2008 update - a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008 Jan 29; 117 (4): e25-146
2. Munger MA, Hawkins DW. Atherothrombosis: epidemiology, pathophysiology, and prevention. J Am Pharm Assoc (Wash) 2004 Mar-Apr; 44 (2 Suppl. 1): S5-12
3. Duvall WL, Vorchheimer DA. Multi-bed vascular disease and atherothrombosis: scope of the problem. J Thromb Thrombolysis 2004 Feb; 17 (1): 51-61
4. Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994 Dec; 1 (4): 333-9
5. Clagett GP, Sobel M, Jackson MR, et al. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 609S-26S
6. Toscani MR, Makkar R, Bottorff MB. Quality improvement in the continuum of care: impact of atherothrombosis in managed care pharmacy. J Manag Care Pharm 2004 Nov; 10 (6 Suppl. A): S2-12
7. McCann A. Antiplatelet therapy after coronary occlusion. Aust Prescr 2007; 30: 92-6
8. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myo-cardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007 Aug 14; 116 (7): e148-304
9. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused update of the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society: en-dorsedby the American AcademyofFamily Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee. Circulation 2008 Jan 15; 117 (2): 296-329
10. King 3rd SB, Smith Jr SC, Hirshfeld Jr JW, et al. 2007 Focused update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 writing group to review new evidence and update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, writing on behalf of the 2005 Writing Committee. Circulation 2008 Jan 15; 117 (2): 261-95
11. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008 May; 39 (5): 1647-52
12. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary. A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to develop Guidelines for the Management of Patients with Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006 Mar 21; 47 (6): 1239-312
13. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest 2008 Jun; 133 (6 Suppl.): 630S-69S
14. Goodman SG, Menon V, Cannon CP, et al. Acute ST-segment elevation myocardial infarction. American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest 2008 Jun; 133 (6 Suppl.): 708S-75S
15. Harrington RA, Becker RC, Cannon CP, et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes. American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest 2008 Jun; 133 (6 Suppl.): 670S-797S
16. Sobel M, Verhaeghe R. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest 2008 Jun; 133 (6 Suppl.): 815S-43S
17. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006 Jun 20; 113 (24): 2803-9
18. Adams Jr HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 2007 May 22; 115 (20): e478-534
19. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 Nov 16; 348 (9038): 1329-39
20. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 Apr 20; 354 (16): 1706-17
21. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 Aug 16; 345 (7): 494-502
22. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001 Aug 18; 358 (9281): 527-33
23. Steinhubl SR, Berger PB, Mann 3rd JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002 Nov 20; 288 (19): 2411-20
24. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005 Nov 5; 366 (9497): 1607-21
25. Sabatine MS, Cannon CP, Gibson CM, etal. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005 Mar 24; 352 (12): 1179-89
26. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreat-ment before percutaneous coronary intervention inpatients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005 Sep 14; 294 (10): 1224-32
27. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996 Nov; 143 (1-2): 1-13
28. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004 Jul 24-30; 364 (9431): 331-7
29. Halkes PH, van Gijn J, Kappelle LJ, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemiaofarterial origin (ESPRIT): randomised controlled trial. Lancet 2006 May 20; 367 (9523): 1665-73
30. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. NEngl J Med 2007 Nov 15; 357 (20): 2001-15
31. Sacco R, Diener HC, Yusuf S, on behalf of the Steering Committee and PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008 Sep 18; 359 (12): 1238-51
32. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 Jan 12; 324 (7329): 71-86
33. Ariesen MJ, Algra A, Kappelle LJ. Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. Stroke 2006 Jan; 37 (1): 134-8
34. Chang YJ, Ryu SJ, Lee TH. Dose titration to reduce dipyridamole-related headache. Cerebrovasc Dis 2006; 22 (4): 258-62
35. Bertrand OF, Larose E, Rodés-Cabau J, et al. Incidence, predictors, and clinical impact of bleeding after transradial coronary stenting and maximal antiplatelet therapy. Am Heart J 2009 Jan; 157 (1): 164-9
36. Byrne J, Spence MS, Fretz E, et al. Body mass index, periprocedural bleeding, and outcome following percutaneous coronary intervention (from the British Columbia Cardiac Registry). Am J Cardiol 2009 Feb 15; 103 (4): 507-11
37. Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008 Feb 19; 51 (7): 690-7
38. Rao SV. Implications of bleeding and blood transfusion in percutaneous coronary intervention. Rev Cardiovasc Med 2007; 8 Suppl. 3: S18-26
39. Bowry AD, Brookhart MA, Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as comparedto antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol 2008 Apr 1; 101 (7): 960-6
40. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008 Sep 18; 359 (12): 1238-51
41. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005 Jan 18; 45 (2): 246-51
42. De Miguel A, Ibanez B, Badimón JJ. Clinical implications of clopidogrel resistance. Thromb Haemost 2008 Aug; 100 (2): 196-203
43. Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008 Sep; 100 (3): 379-90
44. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clo-pidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008 Apr 8; 51 (14): 1404-11
45. Kuliczkowski W, Witkowski A, Polonski L, et al. Interindividual variability in the response tooral antiplatelet drugs:a position paperofthe Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis ofthe European Society of Cardiology. Eur Heart J 2009 Feb; 30 (4): 426-35
46. Pallares MJ, Powers ER, Zwerner PL, et al. Barriers to clopidogrel adherence following placement of drug-eluting stents. Ann Pharmacother 2009 Feb; 43 (2): 259-67
47. von Tiehl KF, Price MJ, Valencia R, et al. Clopidogrel desensitization after drug-eluting stent placement. J Am Coll Cardiol 2007 Nov 20; 50 (21): 2039-43
48. Douen AG, Medic S, Sabih M, et al. Titrated initiation of acetylsalicylic acid-dipyridamole therapy reduces adverse effects and improves tolerance in patients with stroke. J Stroke Cerebrovasc Dis 2008 Nov-Dec; 17 (6): 356-9
49. Schleinitz MD, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med 2004 Jun 15; 116 (12): 797-806
50. Cheng JW. Pharmacoeconomic analysisofclopidogrel in secondary prevention of coronary artery disease. J Manag Care Pharm 2007 May; 13 (4): 326-36
51. Jones L, Griffin S, Palmer S, et al. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess 2004 Oct; 8 (38): iii-iv, 1-196
52. Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). AmJCardiol 2001 Apr 1;87 (7): 819-22
53. Ovbiagele B, Saver JL, Fredieu A, et al. PROTECT: a coordinated stroke treatment program to prevent recurrent thromboembolic events. Neurology 2004 Oct 12; 63 (7): 1217-22
54. Ovbiagele B, Saver JL, Fredieu A, et al. In-hospital initiation of secondary stroke preventiontherapies yields high rates ofadherence at follow-up. Stroke 2004 Dec; 35 (12): 2879-83
55. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) initiative. JAMA 2002 Mar 13; 287 (10): 1269-76
56. McCarthy M. US heart-guidelines strategy makes promising start. Lancet 2001 Nov 10; 358 (9293): 1618
57. Staman K, Roe MT, Fraulo ES, et al. Quality improvement tools designed to improve adherence to ACC/AHA guidelines for the care of patients with non-ST-segment acute coronary syndromes. Crit Pathways Cardiol 2003 Mar; 2: 34-40
58. Marciniak TA, Ellerbeck EF, Radford MJ, et al. Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. JAMA 1998 May 6; 279 (17): 1351-7
59. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000 Dec; 36 (7): 2056-63
60. CRUSADE. The CRUSADE National Quality Initiative [online]. Available from URL: http://www.crusadeqi.com/ [Accessed 2006 Sep 11]
61. Peterson ED, Roe MT, Lytle BL, et al. The association between care and outcomes in patients with acute coronary syndromes: national results from CRUSADE [abstract no. 1077-71]. J Am Coll Cardiol 2004; 43: 406A
62. American Stroke Association. AVAIL study for GWTG-stroke hospitals [online]. Available from URL: http://www.strokeassociation.org/presenter. jhtml?identifier=3039649 [Accessed 2008 Feb 5]